Grass is turning greener again
After years of dashed euphoria, the cannabis market is making a comeback. With federal reclassification in the United States and regulated legalization in Europe, the sector is emerging from a long downturn. However, this resurgence is contingent on political decisions and the ability of companies to finally achieve profitability.
The Hype Around Cannabis Stocks is a Thing of the Past
Between 2019 and 2023, the sector's stars—Tilray Brands, Cronos Group, Aurora Cannabis—saw their market capitalizations plummet by 80 to 90%. The promises of a green eldorado were swept away by regulatory hurdles and the lack of sustainable profits. Investors, having cooled off, deserted a market that had become synonymous with volatility and disillusionment. But since the end of 2024, a breeze of cautious optimism is blowing once more. Driven by strong political initiatives, sector stocks are bouncing back. In the United States, the administration is considering reclassifying cannabis from Schedule I to Schedule III, marking a historic shift. This change in status—which would place medical cannabis on the same level as some legal opioids—would open access to traditional banking services, allow for tax-deductibility of expenses, and finally make the sector investable for institutions.
This regulatory shift coincides with a global movement
Several US states continue to expand the legalization of recreational cannabis, while Europe is cautiously embracing regulated consumption. In April 2024, Germany legalized home cultivation and personal consumption in controlled clubs, sparking a wave of interest in neighboring countries. In France, the debate remains on the fringe, but medical trials are making progress.
Regulation is a game changer
If regulatory changes are game-changers, structural demand is the other driver of renewal. In the medical market, cannabis is gradually becoming established in the treatment of pain, anxiety, and certain chronic illnesses. In the recreational segment, habits are evolving: consumption is no longer limited to flowers or resin but now includes derivative products—infused beverages, oils, cosmetics, dietary supplements—that are more integrated into daily routines. This diversification broadens the market and attracts new consumers who are more interested in quality and traceability than in seeking a psychoactive effect.
This content has been automatically translated using artificial intelligence. While we strive for accuracy, some nuances may differ from the original French version.
